Login to Your Account



Grecian ‘earn’: $70M for Melinta’s antibiotic program in phase III

By Randy Osborne
Staff Writer

Tuesday, February 11, 2014
The ability to seamlessly switch patients from an intravenous (I.V.) to an oral version of the same, broad-spectrum antibiotic could give Melinta Therapeutics Inc. a leg up in the field, and the company raised $70 million to help find out whether phase III-stage fluoroquinolone delafloxacin will make the grade.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription